Marlise Rachael Luskin, MD, MSCE, discusses the rationale, structure, and toxicity considerations of pediatric-inspired regimens in AYA ALL.
Marlise Rachael Luskin, MD, MSCE
Advertisement
Articles by Marlise Rachael Luskin, MD, MSCE
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
Dr Mayer on the FDA Approval of Camizestrant for ESR1-Mutated Breast Cancer
3
INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management
4
IDMC Recommends Continuation of Phase 2 MRD Study of IMNN-001 in Advanced Ovarian Cancer
5